| 18.7436 -0.096 (-0.51%) | 03-12 15:37 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 24.28  |
1-year : | 26.27 |
| Resists | First : | 20.78 |
Second : | 22.5 |
| Pivot price | 20.08 |
|||
| Supports | First : | 18.02 |
Second : | 14.99 |
| MAs | MA(5) : | 19.48 |
MA(20) : | 20.31 |
| MA(100) : | 21.73  |
MA(250) : | 17.04 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 22.6 |
D(3) : | 31.8 |
| RSI | RSI(14): 40.7 |
|||
| 52-week | High : | 30 | Low : | 3.42 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ URGN ] has closed above bottom band by 14.4%. Bollinger Bands are 27.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19.26 - 19.42 | 19.42 - 19.52 |
| Low: | 18.22 - 18.39 | 18.39 - 18.5 |
| Close: | 18.61 - 18.88 | 18.88 - 19.06 |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Mon, 09 Mar 2026
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Fri, 06 Mar 2026
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Tue, 03 Mar 2026
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Tue, 03 Mar 2026
Urogen Pharma (NASDAQ:URGN) Shares Gap Up Following Earnings Beat - MarketBeat
Tue, 03 Mar 2026
UroGen Pharma (URGN) Quarterly Loss Narrows To US$0.54 EPS Challenging Bearish Narratives - Sahm
Mon, 02 Mar 2026
Oppenheimer Maintains Outperform on UroGen Pharma Ltd. (URGN) March 2026 - Meyka
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 47 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 97.8 (%) |
| Shares Short | 9,340 (K) |
| Shares Short P.Month | 10,570 (K) |
| EPS | -3.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.19 |
| Profit Margin | -139.9 % |
| Operating Margin | -50.6 % |
| Return on Assets (ttm) | -32.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 54 % |
| Gross Profit (p.s.) | 2.07 |
| Sales Per Share | 2.34 |
| EBITDA (p.s.) | -2.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -162 (M) |
| Levered Free Cash Flow | -99 (M) |
| PE Ratio | -5.41 |
| PEG Ratio | 0 |
| Price to Book value | -8.61 |
| Price to Sales | 7.99 |
| Price to Cash Flow | -5.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|